Nuclear Medicine Explained: Diagnosis and Treatment with Radiation

Diagnostic Nuclear Medicine

Diagnostic nuclear medicine works by introducing a small amount of radioactive material into the body, usually by intravenous injection, and then detecting the gamma rays it emits using specialized cameras. Unlike X-rays or CT scans that show anatomy (structure), nuclear medicine shows physiology (function), revealing how organs and tissues are actually working. A bone scan can detect stress fractures invisible on X-ray weeks before structural changes become apparent. A cardiac perfusion scan reveals which areas of heart muscle receive adequate blood flow during rest and stress, identifying coronary artery disease before a heart attack occurs. A thyroid scan shows which parts of the gland are overactive or underactive, distinguishing between different causes of hyperthyroidism that require different treatments.

The gamma camera (also called an Anger camera after its inventor Hal Anger) is the primary imaging device in conventional nuclear medicine. It consists of a large flat crystal of sodium iodide (typically 40-50 cm in diameter) that converts incoming gamma rays into flashes of visible light, detected by an array of photomultiplier tubes. Electronics determine the location and energy of each detected gamma ray, building up an image over several minutes of acquisition time. Single-photon emission computed tomography (SPECT) rotates the gamma camera around the patient, acquiring projections from multiple angles to reconstruct a three-dimensional image of isotope distribution, similar in principle to CT scanning but imaging the radiation emitted from within the body rather than transmitted through it.

Technetium-99m (Tc-99m) is the workhorse of diagnostic nuclear medicine, used in over 80% of all nuclear imaging procedures worldwide, totaling more than 30 million scans annually. Its properties are nearly ideal: it emits a 140 keV gamma ray (energetic enough to escape the body but low enough for efficient camera detection), has a 6-hour half-life (long enough for imaging but short enough to limit patient dose), and can be chemically attached to dozens of different carrier molecules that target specific organs. Tc-99m labeled to phosphonate compounds accumulates in bone, revealing fractures and metastases. Attached to sestamibi, it concentrates in heart muscle proportional to blood flow. Bound to sulfur colloid, it is taken up by liver cells. This versatility makes a single isotope the basis for imaging virtually every organ system.

Tc-99m is produced from molybdenum-99 generators that can be shipped to hospitals and "milked" daily for fresh technetium, making it available even far from reactor production facilities. The generator exploits the parent-daughter decay relationship: Mo-99 (half-life 66 hours) decays to Tc-99m, which is selectively washed from the generator column with saline. A single generator provides useful quantities of Tc-99m for about one week before the Mo-99 decays below practical levels and the generator is replaced. This elegant supply system means that hospitals need not operate nuclear reactors or cyclotrons to access the most commonly used medical radioisotope.

Positron Emission Tomography (PET)

Positron Emission Tomography (PET) uses isotopes that emit positrons (antimatter electrons). When a positron encounters a normal electron, they annihilate each other, producing two 511 keV gamma rays traveling in exactly opposite directions. Ring-shaped detectors surrounding the patient register these coincident pairs, enabling three-dimensional reconstruction of isotope distribution with resolution of about 4-5 millimeters. The coincidence detection principle (requiring both gamma rays within a narrow time window) provides inherent background rejection and geometric information without physical collimators, giving PET superior sensitivity and resolution compared to SPECT imaging.

Fluorine-18 fluorodeoxyglucose (FDG) is the most common PET tracer, concentrating in metabolically active tissues because cells take it up through the same glucose transporter proteins as normal glucose. Once inside the cell, FDG is phosphorylated but cannot proceed further through glycolysis, becoming trapped and accumulating proportional to glucose metabolic rate. Cancer cells typically have elevated glucose metabolism (the Warburg effect), making FDG-PET extremely sensitive for detecting tumors, staging cancer spread, and monitoring treatment response. A single whole-body FDG-PET scan can simultaneously evaluate every organ for metastatic disease, often replacing multiple conventional imaging studies.

Beyond oncology, PET imaging serves neurology (detecting Alzheimer's disease amyloid plaques years before symptoms, localizing seizure foci in epilepsy), cardiology (assessing myocardial viability to determine which patients benefit from revascularization), and infection imaging (identifying occult sources of fever). Newer PET tracers target specific molecular markers: gallium-68 PSMA for prostate cancer, gallium-68 DOTATATE for neuroendocrine tumors, and florbetapir for brain amyloid deposits. The expanding menu of PET radiopharmaceuticals enables increasingly specific molecular imaging that characterizes disease biology rather than merely detecting anatomical abnormalities.

Therapeutic Nuclear Medicine

Therapeutic nuclear medicine delivers radiation directly to diseased tissue from within the body, a concept called targeted radionuclide therapy. The radioactive atom is attached to a molecule that selectively accumulates in diseased tissue, concentrating cell-killing radiation where it is needed while sparing distant healthy organs. The key advantage over external beam radiotherapy is the ability to treat disseminated disease (metastases scattered throughout the body) simultaneously, something impossible with a focused external beam that can only target one location at a time.

Iodine-131 treatment for thyroid conditions exploits the fact that thyroid cells naturally concentrate iodine from the bloodstream through the sodium-iodide symporter protein. Patients swallow a capsule of radioactive iodine, which accumulates in the thyroid and destroys overactive or cancerous thyroid tissue through beta radiation (average range about 0.4 mm in tissue) while leaving the rest of the body largely unaffected. This treatment has been used successfully since the 1940s and remains the standard of care for differentiated thyroid cancer and Graves disease. Following surgery for thyroid cancer, radioiodine treatment destroys any remaining microscopic thyroid tissue, reducing recurrence rates and enabling long-term monitoring through thyroglobulin blood tests.

Lutetium-177 PSMA therapy represents a newer generation of targeted radiotherapy for metastatic prostate cancer. A radioactive lutetium atom is attached to a molecule that binds specifically to prostate-specific membrane antigen (PSMA), a protein overexpressed on prostate cancer cells. The radiopharmaceutical circulates through the bloodstream, binds to cancer cells wherever they are in the body, and delivers cell-killing beta radiation within a range of about 1-2 millimeters, destroying cancer cells while sparing distant healthy tissue. The VISION clinical trial showed significant survival benefits (median overall survival improved by 4 months), leading to FDA approval in 2022. Patients typically receive 4-6 treatment cycles at 6-week intervals.

Radium-223 dichloride treats bone metastases from prostate cancer by mimicking calcium and incorporating into areas of active bone formation around metastatic deposits. Its alpha radiation (high energy deposited over very short range of 2-10 cell diameters) destroys nearby cancer cells with minimal damage to surrounding bone marrow. Alpha-emitter therapies represent an active research frontier, with actinium-225 and astatine-211 being investigated for treating various cancers through targeted alpha therapy (TAT). The extremely short range and high biological effectiveness of alpha particles make them particularly promising for destroying individual cancer cells and micrometastases while limiting collateral damage.

Isotope Production and the Theranostic Concept

Medical isotopes come from two main sources: nuclear reactors and particle accelerators. Reactor-produced isotopes include molybdenum-99 (parent of Tc-99m), iodine-131, lutetium-177, and samarium-153. These are created through neutron capture or fission of uranium targets. The global Mo-99 supply depends on a small number of aging research reactors, creating periodic supply vulnerabilities that have driven investment in alternative production methods including accelerator-based approaches and low-enriched uranium targets.

Accelerator-produced isotopes include fluorine-18 (for PET), gallium-68 (for PET imaging of neuroendocrine tumors and prostate cancer), carbon-11, nitrogen-13, and oxygen-15 (all used in research PET). Hospital-based cyclotrons, typically compact machines accelerating protons to 10-30 MeV, produce these short-lived isotopes on-site since their half-lives (110 minutes for F-18, 68 minutes for Ga-68, 20 minutes for C-11) are too short for long-distance shipping. The number of medical cyclotrons worldwide has grown steadily, reaching over 1,500 installations serving diagnostic imaging centers.

The theranostic concept pairs a diagnostic imaging isotope with a therapeutic isotope on the same targeting molecule, enabling physicians to first image the disease (confirming the target is present and the drug accumulates appropriately) and then treat it with the therapeutic version. The PSMA theranostic pair uses gallium-68 PSMA for PET imaging and lutetium-177 PSMA for therapy. Only patients whose PET scans show strong PSMA uptake in their tumors proceed to therapy, ensuring treatment is directed at patients most likely to benefit. This "see it, treat it" paradigm represents a shift toward personalized nuclear medicine where imaging biomarkers guide therapeutic decisions.